#1 Clinical Trials Search in Europe

Study on the Effects of Cannabidiol on the Central Nervous System in Healthy Male Participants

1

What is this study about?

This clinical trial is focused on understanding the effects of a substance called cannabidiol on the central nervous system (CNS) in healthy male participants. Cannabidiol, often referred to as CBD, is a compound found in cannabis plants. The study will use a flavored oil form of CBD, known as Clinican CBD 10% oil flavored, and will compare its effects to a placebo. The main goal is to observe how different doses of CBD, specifically 30 mg and 700 mg, influence certain brain functions and excitability, which refers to how easily the brain responds to stimuli.

Participants will take part in a series of tests designed to measure various aspects of brain activity and function. These tests include the NeuroCart test battery and Transcranial Magnetic Stimulation (TMS), which are methods used to assess brain performance and excitability. The study will look at how CBD affects tasks related to eye movements, memory, and body balance, among others. The trial will also monitor any side effects and changes in vital signs, such as heart rate and blood pressure, throughout the study period.

The study is structured as a randomized, double-blind, placebo-controlled, 3-way cross-over trial. This means that participants will receive different treatments in a random order, and neither the participants nor the researchers will know which treatment is being administered at any given time. The trial aims to provide insights into how CBD might influence brain function and could potentially inform future research or treatments involving CBD.

1 joining the study

Upon joining the study, you will be required to provide a signed informed consent. This is a document that confirms your understanding of the study and your willingness to participate.

You must be a healthy male between the ages of 18 and 55, with a body mass index (BMI) between 18 and 30 kg/m², and a minimum weight of 50 kg.

Effective contraception must be practiced during the study and for at least 90 days after the last dose of the study treatment.

2 initial assessment

An initial assessment will be conducted to ensure you meet all the criteria for participation. This may include a review of your medical history and a physical examination.

You will need to communicate effectively in the Dutch language and comply with study restrictions.

3 medication administration

You will receive a single oral dose of cannabidiol at either 30 mg or 700 mg, or a placebo. A placebo is a substance with no active medication, used to compare effects.

The medication is administered in the form of a solution in oil, taken orally.

4 testing and monitoring

You will undergo various tests to assess the effects of the medication on your central nervous system (CNS). These tests include measuring eye movements, memory tests, and body sway assessments.

Additional tests will measure changes in brain activity using techniques like transcranial magnetic stimulation (TMS).

5 follow-up visits

Throughout the study, you will have follow-up visits to monitor your health and any potential side effects.

Your vital signs, such as pulse rate and blood pressure, will be checked regularly.

6 completion of study

Once all assessments are completed, your participation in the study will conclude.

You will be informed about the results and any further steps if necessary.

Who Can Join the Study?

  • Signed informed consent before any study-related procedure. This means you agree to participate after understanding the study details.
  • Must be a healthy male between 18 and 55 years old.
  • Body mass index (BMI) should be between 18 and 30 kg/m2, and you must weigh at least 50 kg. BMI is a measure of body fat based on height and weight.
  • Must use effective birth control during the study and for at least 90 days after the last dose of the study treatment.
  • Must be able to communicate well with the study doctor in Dutch and be willing to follow the study rules.

Who Cannot Join the Study?

  • Participants must be male.
  • Participants must not be part of a vulnerable population. This means they should not be in a group that might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Centre for Human Drug Research Leiden The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Not recruiting
20.11.2023

Trial locations

Investigated drugs:

Cannabidiol is a compound found in the cannabis plant. In this clinical trial, it is being tested to see how it affects the brain and nervous system. Researchers are interested in understanding how cannabidiol influences certain brain activities and responses. The study uses special tests to measure these effects, which can help determine if cannabidiol has potential benefits for brain health or function. Participants in the trial take cannabidiol orally, meaning they swallow it, and then undergo various tests to see how their brain activity changes.

Investigated diseases:

Neurological assessments – Neurological assessments are evaluations of the nervous system to understand its function and detect any abnormalities. These assessments often involve a series of tests that measure various aspects of brain and nerve function, such as reflexes, motor skills, sensory perception, balance, and cognitive abilities. The progression of findings from these assessments can indicate changes in neurological function over time. They help in identifying issues like memory problems, coordination difficulties, or changes in mental status. The results can guide further investigation into specific neurological conditions. Regular assessments can track the progression of neurological health or disease.

Trial ID:
2023-508311-23-00
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on the Physical Impact of Multiple Sclerosis and Continued Access to Ocrelizumab for Patients Previously in a Related Study

    Recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria France Germany

  • Study on the Effects of Dexmedetomidine on Brain Fluid Flow and Activity in Patients with Neurodegenerative Diseases, Delirium, or Acute Neurological Conditions

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland